Drug Target Review update: exclusive report, online summit and more!
Hear about the latest Drug Target Review updates from Deputy Editor Victoria Rees who discusses our new report on AI & Informatics, the Cell & Gene Therapy Advancements online summit and much more!
Hear Deputy Editor Victoria Rees give an update on the most exciting developments at Drug Target Review!
In our first update, Drug Target Review has produced and published an exclusive report on AI and informatics in drug discovery and development. With deep-dives into the four major themes of imaging, drug design, drug screening and synthetic biology, this in-depth analysis reveals that 79 percent of experts believe the use of AI will increase within drug screening and 75 percent of synthetic biologists say the main benefit of AI and informatics is the ease of data prediction and modelling. To discover more insights, read the full report here.
Secondly, Drug Target Review will be hosting its Cell & Gene Therapy Advancements online summit on 3-4 November later this year. Leading scientists will present their latest research on a range of topics, including immuno-oncology, CRISPR, stem cell therapies, personalised medicine and much more! Join over 1,000 of your colleagues in early biologics discovery and listen to expert speakers from Santen Pharmaceutical Co, Navega Therapeutics, Cornell University and many more! Sign up to reserve your place here.
In another update, we have recently published our latest podcast episode, where Dr Justin Lee from the US Centers for Disease Control and Prevention (CDC), Professor Vasan from Australia’s Commonwealth Scientific and Industrial Research Organisation (CSIRO) and Dr Chantal Vogels from the Yale School of Medicine discuss how to identify and monitor SARS-CoV-2 variants. Listen along here.
Subscribe for FREE here to gain access to all our latest content!
Centers for Disease Control and Prevention (CDC), Commonwealth Scientific and Industrial Research Organisation (CSIRO), Cornell University, Navega Therapeutics, Santen Pharmaceutical Co, Yale School of Medicine